|Mr. Thomas Andrew Crockett||CEO & Director||605.33k||N/A||1975|
|Mr. Benjamin L. Palleiko||Chief Bus. Officer & CFO||334.49k||N/A||1966|
|Mr. Andreas Maetzel M.D., M.Sc., Ph.D.||Sr. VP of Medical||48.62k||N/A||1963|
|Mr. John B. McKune||VP of Fin.||492.02k||N/A||1976|
|Dr. Edward P. Feener||Chief Scientific Officer||N/A||N/A||1960|
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE; and KVD824, an oral plasma kallikrein inhibitor that is in Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.